Medical/Pharmaceuticals
/C O R R E C T I O N -- Piramal Pharma Solutions/
In the news release, Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility, issued 06-Oct-2026 by Piramal Pharma Solutions over PR Newswire, we are advised by the company that changes have been made to the caption accompanying the first ima...
2026-10-06 16:59
3459
Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins
* Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2026 * The trial provided initial safety and tolerability data for Lu AF28996, with most treatment-emergent adverse events reported as mild...
2026-10-06 14:35
3428
Dr. Oregonin Completes U.S. FDA Registration for OLTIS DENTAL-X, Unveiling Oral-Care Innovation Rooted in Trans-Pacific Alder Research
Botanical oral-care product bridges 1974 Oregon State University discovery of 'oregonin' with 27 years of natural-product research by South Korean scientists. SEOUL, South Korea, Oct. 6, 2026 /PRNewswire/ -- Dr. Oregonin Inc. today announced that it has completed U.S. Food and Drug Administration...
2026-10-06 13:50
2693
Docquity Extends Asian Healthcare Intelligence to Japan Through Deepened Strategic Partnership with exMedio
Japan scale up advances Docquity's goal of Asian Healthcare Intelligence built on Clinical Intent, with Ask Dx as the core platform and "One Asia" linking physicians in Japan and Southeast Asia SINGAPORE, Oct. 6, 2026 /PRNewswire/ -- Docquity, the clinical AI platform for more than 75% of verifi...
2026-10-06 11:51
2935
CHANDO Group Presents 20 Research Papers at IFSCC 2026 Congress in Perth
12 years of participation underscore the Group's growing presence in global cosmetics science SHANGHAI and PERTH, Australia, Oct. 6, 2026 /PRNewswire/ -- The 36th Congress of the International Federation of Societies of Cosmetic Chemists (IFSCC) was held in Perth, Australia, from September 28 to...
2026-10-06 11:40
4231
Fapon Showcases High-Performance IVD Raw Materials at JACLaS EXPO 2026
KOBE, Japan, Oct. 6, 2026 /PRNewswire/ -- Fapon, a trusted global IVD provider, will showcase its one-stop IVD solution at JACLaS EXPO 2026, held October 8–10 in Kobe, Japan. Visit Booth B32, Hall 1, 1st Floor. Fapon will spotlight its latest breakthroughs in small molecule sandwich antibodies a...
2026-10-06 08:00
2732
Datasea Reports Fiscal Year 2026 Results with Gross Profit Up 70.1% and Gross Margin Increased to 10.2% Despite Lower Revenue
Net Loss Narrowed 57.0% and Operating Cash Flow Turned Positive; Company Also Received an Additional 180-Day Nasdaq Compliance Period BEIJING, Oct. 5, 2026 /PRNewswire/ -- Datasea Intelligent Technology Ltd. (Nasdaq: DTSS) ("Datasea" or the "Company"), a technology company focused on acoustic in...
2026-10-05 22:13
9374
EpiSign and Geneyx Announce Partnership to Integrate Genomic and Epigenomic Analysis for Rare Disease
Collaboration brings EpiSign's comprehensive DNA methylation episignature analysis together with the Geneyx genomic and multi-omics analysis platform LONDON, ON and HERZLIYA, Israel, Oct. 5, 2026 /PRNewswire/ -- EpiSign Inc. and Geneyx Genomex Ltd. today announced a partnership to advance the in...
2026-10-05 21:52
3641
Estée Lauder at NYSE for Breast Cancer Awareness Month: NYSE Content Update
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Oct. 5, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins...
2026-10-05 21:44
6294
OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.
* OMLYCLO® (omalizumab-igec) is the first and onlyFDA-approved omalizumab biosimilar approved for all four indications of XOLAIR® (omalizumab) and designated as interchangeable with XOLAIR; OMLYCLO® will be available in 75 mg/0.5 mL, 150 mg/mL and 300mg/2mL in a single-dose prefilled syringe fo...
2026-10-05 20:45
4045
Ajinomoto Bio-Pharma Services Unveils Refreshed Global Brand, Showcasing its Strength in Specialization
* Reflects the depth of expertise and innovation Aji Bio-Pharma brings to customers navigating increasingly demanding development and manufacturing challenges TOKYO, Oct. 5, 2026 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a global network of specialized contract developme...
2026-10-05 19:00
4780
Energenesis Biomedical and Yoo Young Pharm Sign MOU for ENERGI-F703DFU Development and Commercialization in Korea
TAIPEI, Oct. 5, 2026 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657) today announced that it has signed a Memorandum of Understanding ("MOU") with Yoo Young Pharm. Co., Ltd. ("YYP"), a South Korea-based pharmaceutical company, to explore a collaboration for the development, registra...
2026-10-05 18:00
2849
EVIDENT Completes Acquisition of CrestOptics S.p.A.
NEEDHAM, Mass., Oct. 5, 2026 /PRNewswire/ -- Evident announced today that it has completed the acquisition of CrestOptics S.p.A., a Rome-based developer and manufacturer of advanced optical imaging systems for spinning disk confocal and super-resolution microscopy. The acquisition broadens Eviden...
2026-10-05 15:20
2365
Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers
Published multicenter study found higher complete wound closure rates and faster healing with Symphony plus standard of care AUCKLAND, New Zealand, Oct. 5, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today announced positive results from a prospec...
2026-10-05 12:46
2865
AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)
The only known investigational therapy for SBMA in Phase 3 development worldwide * AJ201 (rosolutamide) is an investigational oral small molecule designed to address multiple disease mechanisms of spinal and bulbar muscular atrophy (SBMA, or Kennedy's disease) * Following submission of the Ph...
2026-10-05 12:30
3034
MH WellFest Cambodia 2026 Marks a New Chapter in ASEAN Healthcare Connectivity
PHNOM PENH, Cambodia, Oct. 5, 2026 /PRNewswire/ -- Maybank (Cambodia) Plc. and the Malaysia Healthcare Travel Council (MHTC) have concluded MH WellFest Cambodia 2026 at Borey Peng Huoth Eco Park in Phnom Penh. With Peng Huoth as venue partner, the two-day event brought together Cambodian families...
2026-10-05 11:19
3160
Celaid Therapeutics Completes Second Close of Series B Financing Round
Shionogi & Co., Ltd. and Teikoku Ventures, Inc. Join the Round to Accelerate U.S. Clinical Trial Preparations for CLD-001 TOKYO, Oct. 4, 2026 /PRNewswire/ -- Celaid Therapeutics Inc. (Head Office: Bunkyo-ku, Tokyo, Japan; President and CEO: Nobuyuki Arakawa; "Celaid") today announced the complet...
2026-10-05 09:30
2428
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 5, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global collab...
2026-10-05 05:46
4268
SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026
MILAN, Oct. 4, 2026 /PRNewswire/ -- At the European Association for the Study of Diabetes (EASD) 2026, SiBionics presented "See More, Act Earlier," connecting continuous sensing with future diabetes care. Three exhibition chapters shaped this vision: "See More: Beyond Glucose," covering glucose, ...
2026-10-04 10:47
3305
Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy
* First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in human skeletal muscle in a monogenic disease. * Paired muscle biopsies reveal 3.5- to 5.3-fold increases in sarcolemmal utrophin expression,...
2026-10-03 19:30
7097
Week's Top Stories
Most Reposted
Cyient, 3-GIS Partner to Help Telecom and Utility Operators Turn Network Data into Operational Control
[Picked up by 1154 media titles]
2026-11-11 22:00Royal Bank of Canada announces agreement to acquire Yarra Capital Management
[Picked up by 1143 media titles]
2026-11-09 21:00Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1121 media titles]
2026-11-06 22:06
Cision Report Reveals the Consumer Trends Hidden Between Search, Social, and AI
[Picked up by 1109 media titles]
2026-11-09 23:00
Poppi Founders Launch Hydration Brand jetty: NYSE Content Update
[Picked up by 1083 media titles]
2026-11-10 22:17
Most Read
DomoAI Launches InkoAI Agent - One Sentence to Ready-to-Post Video
2026-11-13 13:00
76025
Home Companion Robot Mobo to Debut Globally and Open Pre-orders as AiMOGA Showcases Its Robot Family at the 2026 OMODA & JAECOO International User Summit
2026-11-07 13:49
27405
SILVERSEA MARKS HISTORIC OPENING OF THE CORMORANT AT 55 SOUTH, THE SOUTHERNMOST HOTEL ON EARTH, OFFERING A NEW GATEWAY TO ANTARCTICA
2026-11-07 01:05
15703
